Benefits of direct high-throughput cell counting in immuno-oncology research

Antibody-directed and drug therapies have been on the forefront of immuno-oncology research in the past 15 years. Since the FDA introduced the Breakthrough Therapy Designation in 2016 for novel promising drug therapies, the number of applicants and approved candidates has increased dramatically. As more and more researchers are looking at drug effects in cancer cells and moving forward in drug discovery, they face many challenges in their day to do work. Performing cell cytotoxicity assays for multiple cell lines with single and combination drug therapies is standard practice in immuno-oncology. While many researches use end-point assays such as MTT, XTT, WST, or CellTiter-Glo, others prefer the manual [...]

96- and 384-well Ultra-Low Adhesion Round-Bottom Multi-Well Plates now Available

384-well Ultra-low attachment treatedround bottom multi-well plates 96-well Ultra-low attachment treated round bottom multi-well plates Nexcelom has just released two new products: Ultra-low adhesion  round-bottom plates in 96-well and 384-well formats that are specifically designed for working with 3D tumor spheroids. These clear wall, clear bottom plates were validated with U87 MG cells and tracked using a bright-field imaging technique on the Celigo Image Cytometer. These plates are ideal for single spheroid drug screening assays and can also be used to investigate spheroid invasion with the addition of Matrigel. You can read more about the plates [...]